Drug Profile

Etrasimod - Pfizer

Alternative Names: APD-334; Etrasimod arginine - Pfizer; Etrasimod L-arginine; PF-07915503; VELSIPITY; Verespiti

Latest Information Update: 29 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arena Pharmaceuticals
Developer Arena Pharmaceuticals; Everest Medicines; Pfizer
Class 3-ring heterocyclic compounds; Acetic acids; Amino acids; Anti-inflammatories; Benzene derivatives; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Indoles; Skin disorder therapies; Small molecules
Mechanism of Action Sphingosine 1 phosphate receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Eosinophilic oesophagitis
New Molecular Entity Yes

Marketed Ulcerative colitis
Phase II/III Atopic dermatitis
Phase II Eosinophilic oesophagitis
Discontinued Alopecia areata; Crohn's disease; Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma gangrenosum

18 Jul 2025 Pfizer initiates enrolment in a phase I pharmacokinetics trial (In volunteers) in Belgium (PO) (EUCT2025-520930-44-00)
24 Jun 2025 Registered for Ulcerative colitis (In the elderly, In adolescents, In adults) in Japan (PO)
16 Jun 2025 Pfizer terminates a phase II/III trial in Crohn's disease (In the elderly, In adults) in Argentina, Australia, Austria, Belarus, Belgium, Bosnia-Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Egypt, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Latvia, Lebanon, Lithuania, Malaysia, Mexico, Moldova, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, USA (PO) due to study was prematurely discontinued due to a lack of efficacy in sub-study 1 (NCT04173273) (EudraCT2019-002895-14)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com